Targeting liver enzyme may combat obesity-induced diabetes

Diabetes paraphernalia
Blocking DPP4 in the liver may improve insulin sensitivity in patients with Type 2 diabetes. (Pixabay)

Diabetes drugs such as Merck’s Januvia work by inhibiting an enzyme called DPP4, which is a factor in the disease because it interferes with a hormone that’s vital for insulin production. Researchers at Columbia University Irving Medical Center have discovered a new link between DPP4 and obesity—an insight that could inspire new treatments for Type 2 diabetes.

The Columbia team discovered that in obese mice, the liver boosts its production of DPP4, which then travels to belly fat and prompts inflammation. They demonstrated that they could relieve the inflammation by shutting down DPP4 production in the liver. The mice didn’t lose weight, but their insulin resistance improved. The research was published in the journal Nature.

Interestingly, though, Januvia and other drugs in the “gliptin” class did not reduce fat inflammation in the mice. Lead author Ira Tabas, M.D., Ph.D., believes that the problem is that gliptins act in the gut, not the liver.

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

“But we have some evidence that DPP4 inhibitors in the gut also end up promoting inflammation in fat, said Tabas, a professor at Columbia University Vagelos College of Physicians and Surgeons,” in a press release. “That cancels out the anti-inflammatory effects the drugs may have when they reach inflammatory cells, called macrophages, in the fat."

So could DPP4 inhibitors be redirected to liver cells? Tabas’ team is examining a way to do that with small interfering RNAs (siRNAs) that can turn off the gene that produces DPP4. They’re attaching the siRNAs to sugars that are naturally attracted to liver cells.

RELATED: Gut-brain biotech Kallyope ramps up, bags $66M series B

Manipulating enzymes is a popular idea among researchers searching for new ways to combat diabetes and obesity. In January, a team of Japanese researchers described a type of Sirt2 enzyme that they believe could be targeted to improve glucose uptake in the liver. Scientists at the University of California in San Diego found that enzymes called IKKε and TBK1 are elevated in obese mice—and that they may be able to be controlled with an old asthma drug called amlexanox.

The Columbia researchers believe that DPP4 increases inflammation in fat by interacting with a molecule on macrophages.

“If we could block that interaction, we might be able stop the enzyme from causing inflammation and insulin resistance," Tabas said.

Suggested Articles

A COVID-19 antibody diagnostic developed through a joint venture between Mount Sinai Health System and RenalytixAI has been authorized by the FDA.

Researchers at Northwestern University have trained an AI algorithm to automatically detect the signs of COVID-19 on a basic X-ray of the lungs.

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.